Archives
-
Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT
2026-10-05
This 2024 Journal of Ethnopharmacology study combines network pharmacology with cell and mouse models to examine how Shenqi Fuzheng injection affects glioma proliferation and migration. Its main contribution is the convergence of computational target mapping and experimental evidence implicating SRC/PI3K/AKT signaling, while its preclinical design limits direct conclusions about clinical efficacy, VEGF signaling, or anti-angiogenic treatment.
-
ML216 and WRN Evidence: Five Key Questions
2026-10-05
A source-grounded overview of ML216 as a BLM helicase inhibitor, with careful distinction between BLM and WRN biology, preclinical findings in MSI colorectal cancer, evidence quality, interpretation, and applicability limits.
-
LY2109761, Smad2/3 Signaling, and Evidence Limits
2026-10-04
LY2109761 is described as a TGF-β receptor type I and II dual inhibitor that can be used to investigate receptor-proximal Smad2/3 signaling. This overview compares supplier-reported preclinical applications with findings from a 2022 GDF11 study, emphasizing pathway overlap, receptor-specific differences, evidence strength, and limits on translating biochemical or mouse results to human disease.
-
Safe DNA Gel Stain: Product Overview
2026-10-03
Safe DNA Gel Stain (SKU A8743) is an APExBIO fluorescent DNA and RNA gel stain for visualizing nucleic acids in agarose or acrylamide gels. The supplier describes blue-light and UV excitation, green fluorescence, and reduced-mutagenicity positioning, but no matched peer-reviewed paper evidence is available here.
-
Liposomal Ce6 PDT Drives Pyroptosis in Breast Cancer
2026-10-02
The reference study shows that liposomal Chlorin e6 photodynamic therapy can convert mitochondrial oxidative stress into caspase-1-associated pyroptosis in breast cancer models. Its combination with checkpoint inhibition further links reactive cell death to tumor immune activation, while also identifying formulation, light delivery, and model-specific limitations for translation.
-
Doxycycline Hyclate: Matrix Metalloproteinases Inhibitor
2026-10-01
Doxycycline hyclate is a research-use compound described as a matrix metalloproteinases inhibitor that modulates MMP-2, MMP-8, and MMP-9. In a 12-week male-mouse arsenic model, doxycycline hyclate was associated with preserved blood-brain barrier integrity and improved cognitive outcomes, while product documentation separately reports dengue-virus and malaria-assay activity.
-
15-PGDH Inhibition Preserves Muscle During Weight Loss
2026-10-01
The reference study identifies 15-PGDH inhibition as a complementary strategy for improving muscle repair and strength recovery during semaglutide-associated weight loss. In obese mice, combining a 15-PGDH inhibitor with semaglutide enhanced muscle stem cell activity and regenerated myofiber growth without reducing the weight-loss effect.
-
8-Oxo-GTP in Cell-Free RNA Assays
2026-09-30
Explore how 8-Oxo-GTP can be used to interrogate oxidized ribonucleotide effects in transcription and cell-free translation. This article connects nucleotide-quality control with recent advances in continuous tRNA synthesis and provides practical assay-design guidance.
-
High-Throughput MoA Mapping in Tuberculosis
2026-09-30
Santa Maria et al. connect phenotypic antibacterial screens with broad biophysical target profiling and machine learning to infer mechanisms of action and prioritize actionable chemistry. The study retrospectively recovered known antibacterial mechanisms and prospectively identified nanomolar Mycobacterium tuberculosis dihydrofolate reductase inhibitors, illustrating how integrated screening can reduce target-deconvolution uncertainty.
-
EMD638683: Applied SGK1 Inhibitor Workflows
2026-09-29
EMD638683 enables mechanism-first studies of SGK1 signaling, from NDRG1 phosphorylation and endothelial stiffness to stress-linked cancer phenotypes. This workflow guide pairs concentration planning, orthogonal readouts, and troubleshooting with findings from a vascular-stiffening study.
-
3-Deazaneplanocin (DZNep) Research Workflow
2026-09-29
Build reproducible DZNep experiments around SAHH inhibition, EZH2-linked epigenetic readouts, apoptosis, and tumor-initiating-cell assays. This workflow also shows how receptor-stratified breast cancer designs from a CHK1 study can improve exploratory combination and response analyses without overstating what DZNep has demonstrated.
-
Two-Component Cationic Liposomes for mRNA Vaccines
2026-09-28
Pedersen and colleagues describe a stable two-component cationic liposome system that complexes with mRNA by simple admixture rather than requiring pre-encapsulation in a complex lipid nanoparticle formulation. In a murine E.G7OVA lymphoma model, optimized CAF04:mRNA formulations induced strong antigen-specific CD8+ T-cell responses, delayed tumor growth, and improved survival, while freeze-drying supported longer-term storage.
-
Plant Cell Lysis Buffer: A Workflow for WB and IP
2026-09-28
Preserve plant protein phosphorylation and native complexes with a cold, non-denaturing extraction workflow designed for Western blotting and immunoprecipitation. Practical guidance connects buffer choice to the MAPK10–KRT16 research story while distinguishing study findings from product-specific validation.
-
Indazole and Indole Glucagon Receptor Antagonists
2026-09-27
Lin and colleagues developed indazole- and indole-based glucagon receptor antagonists from the earlier MK-0893 lead, using systematic scaffold and substituent changes to identify compounds with promising in vitro profiles and rat pharmacokinetics. Their lead compound, 16d, reduced glucagon-associated glucose excursions in human-GCGR mouse models after oral dosing, providing preclinical evidence for further evaluation in type 2 diabetes research.
-
Talabostat and the DPP–CARD8 Translational Frontier
2026-09-26
Talabostat mesylate is commonly studied through its DPP4 and FAP biology, but Val-boroPro findings in human T cells add an important interpretive layer: DPP inhibition can also engage CARD8-dependent pyroptosis, particularly in resting T cells. This article connects those mechanisms to practical study design, evidence limits, and translational questions.